Zoekresultaten - Laurence Albigès

Verfijn jouw resultaten
  1. 1
    Nivolumab in renal cell carcinoma: latest evidence and clinical potential

    Nivolumab in renal cell carcinoma: latest evidence and clinical potential door Camille Mazza, Bernard Escudier, Laurence Albigès

    Gepubliceerd in 2016
    Volledige tekst Volledige tekst
    Revisão
    Toevoegen aan favorieten
    Bewaard in:
  2. 2
    Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma

    Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma door Elie Rassy, Ronan Flippot, Laurence Albigès

    Gepubliceerd in 2020
    Volledige tekst Volledige tekst
    Revisão
    Toevoegen aan favorieten
    Bewaard in:
  3. 3
    ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer

    ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer door Karim Fizazi, Laurence Albigès, Yohann Loriot, Christophe Massard

    Gepubliceerd in 2015
    Volledige tekst Volledige tekst
    Revisão
    Toevoegen aan favorieten
    Bewaard in:
  4. 4
    Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma

    Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma door Hassan Izzedine, Lisa Derosa, Gwénaël Le Teuff, Laurence Albigès, Bernard Escudier

    Gepubliceerd in 2015
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  5. 5
    Spectrum of breast cancer metastasis in BRCA1 mutation carriers: highly increased incidence of brain metastases

    Spectrum of breast cancer metastasis in BRCA1 mutation carriers: highly increased incidence of brain metastases door Laurence Albigès, Fabrice André, Corinne Balleyguier, Gonzalo Gomez-Abuin, Agnès Chompret, Suzette Delaloge

    Gepubliceerd in 2005
    Volledige tekst Volledige tekst
    Carta
    Toevoegen aan favorieten
    Bewaard in:
  6. 6
    TiNivo: safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma

    TiNivo: safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma door Laurence Albigès, Philippe Barthélémy, Marine Gross‐Goupil, Sylvie Négrier, Michael N. Needle, Bernard Escudier

    Gepubliceerd in 2020
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  7. 7
    Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma

    Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma door Laurence Albigès, Foucauld Chamming’s, Brigitte Duclos, M. Stern, Robert J. Motzer, Alain Ravaud, P. Camus

    Gepubliceerd in 2012
    Volledige tekst Volledige tekst
    Revisão
    Toevoegen aan favorieten
    Bewaard in:
  8. 8
    Metastatic Renal Cell Carcinoma Treated with Sunitinib: Early Evaluation of Treatment Response Using Dynamic Contrast-Enhanced Ultrasonography

    Metastatic Renal Cell Carcinoma Treated with Sunitinib: Early Evaluation of Treatment Response Using Dynamic Contrast-Enhanced Ultrasonography door Nathalie Lassau, Serge Koscielny, Laurence Albigès, L. Chami, Baya Benatsou, Mohamed Chébil, Alain Roche, Bernard Escudier

    Gepubliceerd in 2010
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  9. 9
    Nivolumab plasma concentration and clearance associated with overall survival in patients with renal cell carcinoma

    Nivolumab plasma concentration and clearance associated with overall survival in patients with renal cell carcinoma door Christophe Maritaz, David Combarel, Cécile Dalban, Louis Blondel, Sophie Broutin, Aurélien Marabelle, Laurence Albigès, Angélo Paci

    Gepubliceerd in 2025
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  10. 10
    Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events

    Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events door Viktor Grünwald, Martin H. Voss, Brian I. Rini, Thomas Powles, Laurence Albigès, Rachel H. Giles, Eric Jonasch

    Gepubliceerd in 2020
    Volledige tekst Volledige tekst
    Revisão
    Toevoegen aan favorieten
    Bewaard in:
  11. 11
    Long-term complete remission with ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients

    Long-term complete remission with ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients door Luc Cabel, Elika Loir, Gwénaëlle Gravis, Pernelle Lavaud, Christophe Massard, Laurence Albigès, Giulia Baciarello, Yohann Loriot, Karim Fizazi

    Gepubliceerd in 2017
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  12. 12
    Radiologic Heterogeneity in Responses to Anti–PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma

    Radiologic Heterogeneity in Responses to Anti–PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma door Guillermo de Velasco, Katherine M. Krajewski, Laurence Albigès, Mark M. Awad, Joaquim Bellmunt, F. Stephen Hodi, Toni K. Choueiri

    Gepubliceerd in 2015
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  13. 13
    ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma

    ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma door Thomas Powles, Laurence Albigès, Axel Bex, Viktor Grünwald, Camillo Porta, Giuseppe Procopio, Manuela Schmidinger, Cristina Suárez, Guillermo de Velasco

    Gepubliceerd in 2021
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  14. 14
    Who dies from prostate cancer?

    Who dies from prostate cancer? door Anna Patrikidou, Yohann Loriot, J-C Eymard, Laurence Albigès, Christophe Massard, E. Ileana, Mario Di Palma, Bernard Escudier, Karim Fizazi

    Gepubliceerd in 2014
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  15. 15
    Renal cell carcinoma

    Renal cell carcinoma door James J. Hsieh, Mark P. Purdue, Sabina Signoretti, Charles Swanton, Laurence Albigès, Manuela Schmidinger, Daniel Y.C. Heng, James Larkin, Vincenzo Ficarra

    Gepubliceerd in 2017
    Volledige tekst
    Revisão
    Toevoegen aan favorieten
    Bewaard in:
  16. 16
    Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)

    Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100) door Yohann Loriot, Diletta Bianchini, E. Ileana, Shahneen Sandhu, Anna Patrikidou, Carmel Pezaro, Laurence Albigès, Gerhardt Attard, Karim Fizazi, Johann S. de Bono, Christophe Massard

    Gepubliceerd in 2013
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  17. 17
    Thermal Ablation Combined with Immune Checkpoint Blockers: A 10-Year Monocentric Experience

    Thermal Ablation Combined with Immune Checkpoint Blockers: A 10-Year Monocentric Experience door Baptiste Bonnet, Louis Tournier, Frédèric Deschamps, Steven Yevich, Aurélien Marabelle, Caroline Robert, Laurence Albigès, Benjamin Besse, V Bonnet, Thierry de Baère, Lambros Tselikas

    Gepubliceerd in 2024
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  18. 18
    Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma

    Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma door Anthony Saroufim, Yosra Messai, Meriem Hasmim, Nathalie Rioux, Roberto Iacovelli, G. Verhoest, Karim Bensalah, J-J Patard, Laurence Albigès, Bruno Azzarone, Bernard Escudier, Salem Chouaı̈b

    Gepubliceerd in 2014
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  19. 19
    Chk1 as a new therapeutic target in triple-negative breast cancer

    Chk1 as a new therapeutic target in triple-negative breast cancer door Laurence Albigès, Aïcha Goubar, Véronique Scott, Cécile Vicier, Céline Lefèbvre, Samar Alsafadi, Frédéric Commo, Mahasti Saghatchian, Vladimir Lazar, Philippe Dessen, Suzette Delaloge, Fabrice André, Virginie Quidville

    Gepubliceerd in 2014
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  20. 20
    Insurance status and disparities in disease presentation, treatment, and outcomes for men with germ cell tumors

    Insurance status and disparities in disease presentation, treatment, and outcomes for men with germ cell tumors door Sarah C. Markt, Carlos Lago‐Hernandez, Rowan Miller, Brandon A. Mahal, Brandon Bernard, Laurence Albigès, Lindsay A. Frazier, Clair J. Beard, Alexi A. Wright, Christopher J. Sweeney

    Gepubliceerd in 2016
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:

Zoekinstrumenten: